{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:25:02Z","timestamp":1790443502232,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Flubromazolam is widely known as highly potent designer benzodiazepine (DBZD). Recently, the two flubromazolam-derived new psychoactive substances (NPS) clobromazolam and bromazolam appeared on the drugs of abuse market. Since no information concerning their toxicokinetics in humans is available, the aims of the current study were to elucidate their metabolic profile and to identify the isozymes involved in their phase I and phase II metabolism. In vitro incubations with pooled human liver S9 fraction were performed and analyzed by liquid chromatography coupled to orbitrap-based high-resolution tandem mass spectrometry (LC\u2013HRMS-MS). Biosamples after the ingestion of bromazolam allowed the identification of metabolites in human plasma and urine as well as the determination of bromazolam plasma concentrations by LC\u2013HRMS-MS using the standard addition method. In total, eight clobromazolam metabolites were identified in vitro as well as eight bromazolam metabolites in vitro and in vivo. Predominant metabolic steps were hydroxylation, glucuronidation and combinations thereof. Alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide are recommended as screening targets in urine. Bromazolam and its alpha-hydroxy metabolite are recommended if conjugate cleavage is part of the sample preparation procedure. The bromazolam plasma concentrations were determined to be 6 and 29 \u03bcg\/L, respectively. Several cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) isozymes were shown to catalyze their metabolic transformations. CYP3A4 was involved in the formation of all phase I metabolites of both NPS, while UGT1A4 and UGT2B10 catalyzed their N-glucuronidation. Several UGT isoforms catalyzed the glucuronidation of the hydroxy metabolites. In conclusion, the determined bromazolam plasma concentrations in the low micrograms per liter range underlined the need for sensitive analytical methods and the importance of suitable urine screening procedures including DBZD metabolites as targets. Such an analytical strategy should be also applicable for clobromazolam.<\/jats:p>","DOI":"10.1093\/jat\/bkaa161","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T19:08:05Z","timestamp":1602184085000},"page":"1014-1027","source":"Crossref","is-referenced-by-count":28,"title":["Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam"],"prefix":"10.1093","volume":"45","author":[{"given":"Lea","family":"Wagmann","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha K","family":"Manier","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Felske","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja M","family":"Gampfer","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus R","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Str. Geb. 46, 66421, Homburg, Germany"},{"name":"Department of Applied Pharmacy, University of Applied Sciences Kaiserslautern, Campus Pirmasens, Carl-Schurz-Str. 10\u201316, 66953, Pirmasens, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2021110915594829100_R1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handbook of Experimental Pharmacology"},{"key":"2021110915594829100_R2","article-title":"Global SMART Update Volume 18","author":"UNODC","year":"2017"},{"key":"2021110915594829100_R3","article-title":"Current NPS Threats Volume II. Vol. UNODC, Vienna","author":"UNODC","year":"2020"},{"key":"2021110915594829100_R4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/164_2018_110","article-title":"Fatal poisonings associated with new psychoactive substances","volume":"252","author":"Kronstrand","year":"2018","journal-title":"Handbook of Experimental Pharmacology"},{"key":"2021110915594829100_R5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.forsciint.2016.09.006","article-title":"Blood concentrations of new designer benzodiazepines in forensic cases","volume":"268","author":"Hoiseth","year":"2016","journal-title":"Forensic Science International"},{"key":"2021110915594829100_R6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam - basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2018","journal-title":"Drug Testing and Analysis"},{"key":"2021110915594829100_R7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","article-title":"Flubromazolam\u2014a new life-threatening designer benzodiazepine","volume":"54","author":"\u0141ukasik-G\u0142\u0119bocka","year":"2016","journal-title":"Clinical Toxicology (Philadelphia, Pa)"},{"key":"2021110915594829100_R8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/dta.2146","article-title":"In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples","volume":"9","author":"Noble","year":"2017","journal-title":"Drug Testing and Analysis"},{"key":"2021110915594829100_R9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/dta.2243","article-title":"Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry","volume":"10","author":"Pettersson Bergstrand","year":"2018","journal-title":"Drug Testing and Analysis"},{"key":"2021110915594829100_R10","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa043","article-title":"Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases","author":"Heide","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2021110915594829100_R11","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa050","article-title":"Driving impairment cases involving etizolam and flubromazolam","author":"Rohrig","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2021110915594829100_R12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00414-017-1541-6","article-title":"Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer","volume":"131","author":"El Balkhi","year":"2017","journal-title":"International Journal of Legal Medicine"},{"key":"2021110915594829100_R13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.forsciint.2016.10.021","article-title":"Looking at flubromazolam metabolism from four different angles: metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry","volume":"274","author":"Wohlfarth","year":"2017","journal-title":"Forensic Science International"},{"key":"2021110915594829100_R14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/jat\/bkaa019","article-title":"Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products","volume":"44","author":"Wagmann","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2021110915594829100_R15","volume-title":"Europol 2016 Annual Report on the Implementation of Council Decision 2005\/387\/JHA. Vol. European Monitoring Centre for Drugs and Drug Addiction","author":"EMCDDA","year":"2016"},{"key":"2021110915594829100_R16","article-title":"Novel benzodiazepines - a review of the evidence of use and harms of novel benzodiazepines. Vol. advisory council on the misuse of drugs","author":"ACMD","year":"2020"},{"key":"2021110915594829100_R17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/jm00197a021","article-title":"6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity","volume":"22","author":"Hester","year":"1979","journal-title":"Journal of Medicinal Chemistry"},{"key":"2021110915594829100_R18","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1135\/cccc19833433","article-title":"Potential hypnotics and anxiolytics: 8-chloro-6-(2-chlorophenyl)-1-[4-(2-methoxyethyl)piperazino]-methyl-4H-s-triazolo[4,3-a]-1,4-benzodiazepine and related compounds","volume":"48","author":"Pol\u00edvka","year":"1983","journal-title":"Collection of Czechoslovak Chemical Communications"},{"key":"2021110915594829100_R19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/dta.2211","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: a review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Testing and Analysis"},{"key":"2021110915594829100_R20","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"2021110915594829100_R21","volume-title":"Mass Spectral Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites","author":"Maurer","year":"2016"},{"key":"2021110915594829100_R22","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00216-011-5032-1","article-title":"Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept","volume":"400","author":"Wissenbach","year":"2011","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"2021110915594829100_R23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/jat\/bkaa010","article-title":"Toxicokinetic studies and analytical toxicology of the new synthetic opioids cyclopentanoyl-fentanyl and tetrahydrofuranoyl-fentanyl","volume":"44","author":"Gampfer","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2021110915594829100_R24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.toxlet.2016.06.013","article-title":"What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?","volume":"258","author":"Wagmann","year":"2016","journal-title":"Toxicology Letters"},{"key":"2021110915594829100_R25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/dta.2463","article-title":"In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases","volume":"11","author":"Pettersson Bergstrand","year":"2019","journal-title":"Drug Testing and Analysis"},{"key":"2021110915594829100_R26","volume-title":"Interpretation of MS-MS Mass Spectra of Drugs and Pesticides","author":"Niessen","year":"2016"},{"key":"2021110915594829100_R27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.toxlet.2017.07.901","article-title":"New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-alpha-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine","volume":"280","author":"Richter","year":"2017","journal-title":"Toxicology Letters"},{"key":"2021110915594829100_R28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1124\/dmd.109.030676","article-title":"Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes","volume":"38","author":"Bourcier","year":"2010","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"2021110915594829100_R29","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1124\/dmd.113.051565","article-title":"Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4","volume":"41","author":"Kato","year":"2013","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"2021110915594829100_R30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenetics and Genomics"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaa161\/34299541\/bkaa161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/45\/9\/1014\/41116188\/bkaa161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/45\/9\/1014\/41116188\/bkaa161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T16:00:02Z","timestamp":1636473602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/45\/9\/1014\/5922474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,10,13]]},"published-print":{"date-parts":[[2021,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaa161","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,10,13]]}}}